| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
Department of Obstetrics & Gynecology, Chang-Gung University Medical School, Chang-Gung Memorial Hospital, Lin-Kou Medical Center, Tao-Yuan 333, Taiwan
Address all correspondence and requests for reprints to: Hsin-Shih Wang, M.D., Ph.D., Department of Obstetrics & Gynecology, Chang-Gung Memorial Hospital, Lin-Kou Medical Center, 5 Fu-Hsing Street, Kwei-Shan, Tao-Yuan 333, Taiwan. E-mail: . hswang86{at}ms17.hinet.net
Abstract
Ovarian hyperstimulation syndrome (OHSS), a life-threatening complication occurring in stimulated ovarian cycles, arises from treatment with gonadotropin for induction of follicular maturation in infertile women. Clinical characteristics of OHSS include ascites and pleural effusion induced by increased vascular permeability, where vascular endothelial growth factor (VEGF) was suspected to be the culprit. To test whether the effects of human CG (hCG) on the pathogenesis of OHSS were mediated through the VEGF produced by luteinized granulosa cells, we measured estradiol, VEGF, IGF-II levels in serum, and follicular fluid and analyzed their mRNA expression in luteinized granulosa cells obtained from 101 women (58 with OHSS and 43 controls) who underwent in vitro fertilization and embryo transfer. This study presents the first evidence that hCG up-regulated VEGF expression of granulosa cells in the OHSS, not the control groups, and that follicular VEGF worked through an autocrine mechanism using its kinase insert domain-containing receptor, not the fms-like tyrosine kinase receptor. We calculated total follicular production of VEGF, by multiplying follicular concentrations by follicular volumes, and verified that an increase in total follicular production of VEGF accounted for elevated serum levels of VEGF, which was associated with the development of OHSS. These findings demonstrate that through up-regulation of VEGF, hCG plays a significant role in the pathogenesis of OHSS.
This article has been cited by other articles:
![]() |
P. Humaidan, E.G. Papanikolaou, and B.C. Tarlatzis GnRHa to trigger final oocyte maturation: a time to reconsider Hum. Reprod., October 1, 2009; 24(10): 2389 - 2394. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rodewald, D. Herr, W.C. Duncan, H.M. Fraser, G. Hack, R. Konrad, F. Gagsteiger, R. Kreienberg, and C. Wulff Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability Hum. Reprod., May 1, 2009; 24(5): 1191 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Costa and D. Colia Treating infertility in autoimmune patients Rheumatology, June 1, 2008; 47(suppl_3): iii38 - iii41. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Binder, R. Dittrich, I. Hager, A. Muller, S. Oeser, M. W Beckmann, M. Hamori, P. A Fasching, and R. Strick Association of FSH receptor and CYP19A1 gene variations with sterility and ovarian hyperstimulation syndrome Reproduction, January 1, 2008; 135(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Alvarez, I. Alonso-Muriel, G. Garcia, J. Crespo, J. Bellver, C. Simon, and A. Pellicer Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study Hum. Reprod., December 1, 2007; 22(12): 3210 - 3214. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.D. Taylor, H. Wilson, S.G. Hillier, S.J. Wiegand, and H.M. Fraser Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset Mol. Hum. Reprod., October 1, 2007; 13(10): 729 - 736. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Alvarez, L. Marti-Bonmati, E. Novella-Maestre, R. Sanz, R. Gomez, M. Fernandez-Sanchez, C. Simon, and A. Pellicer Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2931 - 2937. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kosaka, H. Fujiwara, S. Yoshioka, and S. Fujii Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome Hum. Reprod., June 1, 2007; 22(6): 1647 - 1651. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Manau, F. Fabregues, J. Penarrubia, M. Creus, F. Carmona, G. Casals, W. Jimenez, and J. Balasch Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF Hum. Reprod., March 1, 2007; 22(3): 669 - 675. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Gomez, M. Gonzalez-Izquierdo, R. C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, J. Sanchez-Criado, J. Remohi, C. Simon, and A. Pellicer Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model Endocrinology, November 1, 2006; 147(11): 5400 - 5411. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tang, J. Glanville, N. Orsi, J. H. Barth, and A. H. Balen The use of metformin for women with PCOS undergoing IVF treatment Hum. Reprod., June 1, 2006; 21(6): 1416 - 1425. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Babayof, E. J. Margalioth, M. Huleihel, A. Amash, E. Zylber-Haran, M. Gal, B. Brooks, T. Mimoni, and T. Eldar-Geva Serum inhibin A, VEGF and TNF{alpha} levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial Hum. Reprod., May 1, 2006; 21(5): 1260 - 1265. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Manno Can we eliminate severe ovarian hyperstimulation syndrome? Comment I Hum. Reprod., August 1, 2005; 20(8): 2368 - 2369. [Full Text] [PDF] |
||||
![]() |
J. Greenaway, P. A. Gentry, J.-J. Feige, J. LaMarre, and J. J. Petrik Thrombospondin and Vascular Endothelial Growth Factor Are Cyclically Expressed in an Inverse Pattern During Bovine Ovarian Follicle Development Biol Reprod, May 1, 2005; 72(5): 1071 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. I. Rini and E. J. Small Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma J. Clin. Oncol., February 10, 2005; 23(5): 1028 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Fraser, H. Wilson, J. S. Rudge, and S. J. Wiegand Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1114 - 1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.A. Garcia-Velasco, A. Zuniga, A. Pacheco, R. Gomez, C. Simon, J. Remohi, and A. Pellicer Coasting acts through downregulation of VEGF gene expression and protein secretion Hum. Reprod., July 1, 2004; 19(7): 1530 - 1538. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Greenaway, K. Connor, H. G. Pedersen, B. L. Coomber, J. LaMarre, and J. Petrik Vascular Endothelial Growth Factor and Its Receptor, Flk-1/KDR, Are Cytoprotective in the Extravascular Compartment of the Ovarian Follicle Endocrinology, June 1, 2004; 145(6): 2896 - 2905. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Vasseur, P. Rodien, I. Beau, A. Desroches, C. Gerard, L. de Poncheville, S. Chaplot, F. Savagner, A. Croue, E. Mathieu, et al. A Chorionic Gonadotropin-Sensitive Mutation in the Follicle-Stimulating Hormone Receptor as a Cause of Familial Gestational Spontaneous Ovarian Hyperstimulation Syndrome N. Engl. J. Med., August 21, 2003; 349(8): 753 - 759. [Full Text] [PDF] |
||||
![]() |
R. Gomez, C. Simon, J. Remohi, and A. Pellicer Administration of Moderate and High Doses of Gonadotropins to Female Rats Increases Ovarian Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 Expression that Is Associated to Vascular Hyperpermeability Biol Reprod, June 1, 2003; 68(6): 2164 - 2171. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |